Group 1 - The company expects to raise approximately HKD 1.567 billion from the subscription, with a net amount of about HKD 1.554 billion [1] - 90% of the net proceeds will be allocated to research and development expenses, including accelerating clinical studies for new drugs in China and the United States, as well as supporting the expansion of new indications for approved innovative drugs [1] - The remaining 10% of the net proceeds will be used for working capital and general corporate purposes [1] Group 2 - Simcere Pharmaceutical Holding Limited and the company have entered into a placement and subscription agreement, with the seller selling 121 million shares at a price of HKD 12.95 per share, representing approximately 4.89% of the total shares issued as of the announcement date [3] - The company will issue an equal number of shares to the seller at the same subscription price of HKD 12.95 per share [3]
先声药业拟配售总筹15.67亿港元